Alan S. Wayne, MD

Chair, Department of Pediatrics

Professor of Pediatrics, Medicine, and Cancer Biology, Keck School of Medicine of USC

Pediatrician-in-Chief and Senior Vice President of Academic Affairs

Pasadena Guild Chair Children's Hospital Los Angeles

Image of Alan S. Wayne, MD
Is this your profile? Click to edit

Overview

Alan S. Wayne, MD serves as Chair of the Department of Pediatrics at the Keck School of Medicine of USC and Senior Vice President of Academic Affairs and Pediatrician-in-Chief at Children’s Hospital Los Angeles (CHLA). Dr. Wayne is Professor of Pediatrics and Medicine at the Keck School of Medicine of USC. In these roles, Dr. Wayne oversees the Department’s clinical care delivery, medical education, and research programs, and leads the departmental strategy, faculty affairs, and budget management in the context of the missions of USC and CHLA.

Dr. Wayne’s primary research efforts are directed toward the development of new treatment approaches for leukemias and lymphomas, with a focus on targeted, immune-based, and cellular therapies. He is the Medical Director of the Therapeutic Advances in Childhood Leukemia/Lymphoma (TACL) Consortium, a multinational clinical trials group headquartered at CHLA. He has an ongoing leadership role in the development of genetically modified chimeric antigen receptor (CAR) T-cells for childhood hematologic malignancies. Additionally, he plays a leadership role in international efforts in the area of post-transplant relapse of hematologic malignancies, the primary aim of which is to study the biology, prevention, and treatment of relapse after hematopoietic stem cell transplantation.

Board-certified in pediatric hematology-oncology, Dr. Wayne attended the Honors Program in Medical Education obtaining his BS and MD degrees from Northwestern University. He conducted internship, residency, and chief residency in pediatrics at Boston Children’s Hospital followed by pediatric hematology-oncology fellowship at Boston Children’s Hospital and the Dana-Farber Cancer Institute.

Research Funding

  • Randomized study of low versus moderate dose busulfan in transplant for severe combined immunodeficiency
    NIH · U01AI126612 · Aug 24, 2017 – Jul 31, 2024 · Role: Principal Investigator
  • University of Southern California Norris Comprehensive Cancer Center Support Grant (CCSG)
    NIH · P30CA014089 · Apr 1, 1980 – Nov 30, 2026 · Role: Principal Investigator
  • Pediatric Graft-vs-Host Disease
    NIH · Z01BC010596 · Role: Principal Investigator
  • Pediatric Oncology Branch Clinical Care and Education
    NIH · Z01BC010764 · Role: Principal Investigator
  • Experimental Therapeutics of Pediatric Hematopoietic Malignancies
    NIH · Z01SC010353 · Role: Principal Investigator
  • Pediatric Graft-vs-Host Disease
    NIH · ZICBC010596 · Role: Principal Investigator
  • Behavioral Science Core
    NIH · ZICBC011288 · Role: Principal Investigator
  • Experimental Therapeutics of Pediatric Hematopoietic Malignancies
    NIH · ZICSC010353 · Role: Principal Investigator
  • Pediatric Oncology Branch Clinical Care and Education
    NIH · ZIEBC010764 · Role: Principal Investigator

Publications

  • Ixazomib with chemotherapy for childhood relapsed acute lymphoblastic leukemia: a TACL consortium report. Blood Neoplasia. 2026 Aug; 3(3):100247.. View in PubMed
  • Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies. Blood. 2025 Sep 04; 146(10):1163-1173.. View in PubMed
  • Outcomes of PLAT-02 and PLAT-03: evaluating CD19 CAR T-cell therapy and CD19-expressing T-APC support in pediatric B-ALL. Blood. 2025 Aug 14; 146(7):789-801.. View in PubMed
  • Feasibility and favorable responses after investigational CAR T-cell therapy for relapsed and refractory infant ALL. Blood Adv. 2025 May 13; 9(9):2068-2078.. View in PubMed
  • Vincristine Sulfate Liposome Injection With Combination Chemotherapy for Children, Adolescents, and Young Adults With Relapsed Acute Lymphoblastic Leukemia: A Therapeutic Advances in Childhood Leukemia and Lymphoma Consortium Trial. Pediatr Blood Cancer. 2025 May; 72(5):e31584.. View in PubMed
  • CD33-CD123 IF-THEN Gating Reduces Toxicity while Enhancing the Specificity and Memory Phenotype of AML-Targeting CAR-T Cells. Blood Cancer Discov. 2025 01 08; 6(1):55-72.. View in PubMed
  • Optimizing early phase clinical trial washout periods: a report from the Therapeutic Advances in Childhood Leukemia and Lymphoma consortium. J Natl Cancer Inst. 2024 Nov 01; 116(11):1721-1729.. View in PubMed
  • Anti-CD7 allogeneic WU-CART-007 in patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma: a phase 1/2 trial. Res Sq. 2024 Aug 05.. View in PubMed
  • Progression of brain injuries associated with methotrexate chemotherapy in childhood acute lymphoblastic leukemia. Pediatr Res. 2025 Jan; 97(1):348-359.. View in PubMed
  • Enhancing pediatric access to cell and gene therapies. Nat Med. 2024 07; 30(7):1836-1846.. View in PubMed